ESIN TUNA

• Development Of Conceptual Models / ISPOR 19th Annual European Congress (Vienna, Austria) – 11.2016
• Pharmacoeconomic Modeling & Applications / ISPOR 19th Annual European Congress (Vienna, Austria) – 11.2016
• Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications / ISPOR 18th Annual European Congress (Milan, Italy) – 11.2015
• Risk-Sharing/Performance-Based Arrangements For Drugs And Other Medical Products / ISPOR 17th Annual European Congress (Amsterdam, Holland) – 11.2015
• The 5 Choices to Extraordinary Productivity – Franklin Covey – 11.2013

2 articles, 1 book chapter and 46 posters published in international platforms

ARTICLES 

1. Results of Reference Pricing and Reimbursement Discount Rate Schemes of Turkey Farmeconomia, 2013, Vol 14, No 2 

2. Cost of Treatment of Chronic Spontaneous Urticaria in Turkey Health, 2016, 8, 1098- 1103 

BOOK CHAPTER 

1. Tuna E., Market Access in North Eastern Europe Countries. In: Pharmaceutical Market Access in Emerging Markets, Koçkaya G., Wertheimer A., 2016, p.95-129 https://www.seedmedicalpublishers.com/wpcontent/uploads/preview/Pharmaceutical_Market_Access_in_Emerging_Markets.pdf 

POSTERS 

1. Comparing Cost of Therapeutic Plasma Exchange and Intravenous Immunoglobulin Infusion in Treating Guillain-Barre Syndrome / Research abstract for the ISPOR 15th Annual European Congress 3-7 November 2012 in Berlin/ GERMANY 

2. Possible Budget Impact of Internal Reference Pricing for Statins in Turkey / Research abstract for the ISPOR 15th Annual European Congress, 3-7 November 2012 in Berlin/ GERMANY 

3. Net Tax Revenue with a National Based Rotavirus Vaccination Program in Turkey / Research abstract for the ISPOR 15th Annual European Congress, 3-7 November 2012 in Berlin/ GERMANY 

4. The Cost-of-Disease of Thromboembolic and Hemorrhagic Complications Associated with Atrial Fibrillation and its Treatment in Turkey: An Expert Panel Approach for Estimation of Costs / Research abstract for the ISPOR 18th Annual International Meeting, 18-22 May 2013 in New Orleans/ LA/ USA 

5. The Cost-of-Disease of Deep Venous Thrombosis and Its Short and Long-Term Clinical Consequences in Turkey: An Expert Panel Approach for Estimation of Costs / Research abstract for the ISPOR 18th Annual International Meeting, 18-22 May 2013 in New Orleans/ LA/ USA 

6. The Cost–Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients with Atrial Fibrillation (AF) in Turkey / Research abstract for the ISPOR 18th Annual International Meeting, 18-22 May 2013 in New Orleans/ LA/ USA 

7. The Cost–Effectiveness of Rivaroxaban Compared to Enoxaparin Plus Adjusted-Dose Warfarin for the Treatment of Deep Venous Thrombosis (DVT) in Turkey / Research abstract for the ISPOR 18th Annual International Meeting, 18-22 May 2013 in New Orleans/ LA/ USA 

8. Whether The Treatment Expenditures or The Pharmaceutical Expenditures of Social Security Institution (SSI) Have a Higher Increase Rate Between 2005 and 2011 in Turkey? / Research abstract for the ISPOR 18th Annual International Meeting, 18-22 May 2013 in New Orleans/ LA/ USA 

9. Comparison Retail Prices of Drug Prices Between Turkey and European Countries / Research abstract for the ISPOR 16th Annual European Congress, 2-6 November 2013 in Dublin/ IRELAND 

10. Supplementary Health Insurance in Turkey / Research abstract for the ISPOR 16th Annual European Congress, 2-6 November 2013 at Dublin/ IRELAND

11.How Co-Payment Mechanism Has Changed Patients' Perception Towards OTC Type Products? / Research abstract for the ISPOR 16th Annual European Congress, 2-6 November 2013 in Dublin/ IRELAND 

12. Classification of Drugs Bringing From Abroad in Turkey According to Their ATC Codes/ ISPOR 6th Asia Pacific Conference (6-9 September 2014) - Beijing/ CHINA 

13. Development of HTA In Turkey / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

14. Availability of Risk Sharing Agreements in the Turkish Pharmaceutical Sector / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

15. Cost-Analysis of Chronic Idiopathic Urticaria Disease / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

16. Value of Life And Cost of Pre-Mature Deaths With the Perspective of Productivity As Net Tax Revenue for Turkey / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

17. Value of Life And Cost of Pre-Mature Deaths With the Perspective of Productivity As Net Tax Revenue: A Comparison in USA, Canada, Japan and Australia / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

18. Value of Life And Cost of Pre-Mature Deaths With the Perspective of Productivity As Net Tax Revenue: A Comparison in France, Germany, Italy, Spain, United Kingdom / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

19. Value of Life And Cost of Pre-Mature Deaths With the Perspective of Productivity As Net Tax Revenue: A Comparison in Argentina, Brazil and Mexico / Research abstract for the ISPOR 17th Annual European Congress, 8-12 November 2014 at Amsterdam/ NETHERLANDS 

20. Discount Distribution Analysis of Original Medicines Which Has No Generics in Turkey/ Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

21. ATC1 Group Discount Distribution Analysis of Original Medicines Which Has No Generics in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 22. General Assessment of Unlicensed Antineoplastic and Immunomodulating Medicine Usage Subgroups in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

23. General Assessment of Unlicensed Antineoplastic and Immunomodulating Medicine Usage in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7- 11 November 2015 at Milan/ ITALY 

24. General Assessment of Unlicensed Medicine Usage in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

25. Changes in The Prices of Reference Biotechnology Products By The Penetration of Biosimilars into The Turkish Pharmaceutical Market / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

26. Direct Treatment Costs of Stroke in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY

27. Local Cost Study of Treatment of Venous Thromboembolism in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

28. Cost of Familial Mediterranean Fever (FMF) Disease in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

29. How Pricing and Reimbursement Policies Affect The Budget Impact of The Treatment of Systemic Juvenile Idiopathic Arthritis in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

30. Cost Effectiveness of Sodium Oxybate in Treatment of Cataplexy in Patients With Narcolepsy in Turkey / Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

31. Cost Saving Study of Five Grass Pollen Slit Tablet Versus SCIT's & Symptomatic Treatment/ Research abstract for the ISPOR 18th Annual European Congress, 7-11 November 2015 at Milan/ ITALY 

32. Treatment Algorithm and Direct Costs of Treatment of HR+/HER2- Post Menopausal Advanced/Metastatic Breast Cancer Patients in Turkey / Research abstract for the ISPOR 21th Annual International Meeting, 21-25 May 2016 at Washington/ USA 

33. Indirect Costs of Stroke in Turkey / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

34. Direct Costs of Chronic Obstructive Pulmonary Disease (COPD) in Turkey: A Panel Approach / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

35. Adherence to Gold Criteria Strategy in Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients: Cost Implications in Turkey / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

36. Indirect Costs of Epilepsy in Turkey: Cost of The Disease in Terms of Work Loss / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

37. Direct Costs of Epilepsy in Turkey: A Panel Approach / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

38. Indirect Cost of HIV/AIDS: Results of A Survey From A Turkish Research Center / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

39. Direct Cost of HIV/AIDS in Turkey / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

40. Trend of Pharmacoeconomics and Health Outcome Studies in Turkey / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

41. Estimation of Value of Life With A Model Approach Depending on Net Present Value For Turkey / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA 

42. Estimation of Value of Life With a Model Approach Depending on Net Present Value for Austria, Canada, Japan And USA / Research abstract for the ISPOR 19th Annual European Congress, 29 October-2 November 2016 at Vienna/ AUSTRIA

43. Cost of Illness of Spinal Muscular Atrophy in Turkey / Research abstract for the ISPOR Annual European Congress, 12-15 November 2023 at Copenhagen/ DENMARK